The Grand Alliances - A new breed of players, with the ability to turn science into real-world solutions, is on the march. - BioPharm International

ADVERTISEMENT

The Grand Alliances
A new breed of players, with the ability to turn science into real-world solutions, is on the march.


BioPharm International


The life sciences industry continues to move at an astonishing pace. Covering biotechnology, healthcare, pharmaceuticals, informatics, tools, instrumentation, and device companies, the sector draws from a vast, multidisciplinary array of technologies including optical, software, engineering, electronics, and nanotechnology.


David Gow of Touch Bionics, part of a new generation of commercially savvy convergence companies
Today, we are witnessing the rise of a relatively new breed of life science players—dubbed "convergence" companies—who combine this extraordinary diversity of skill sets with the commercial savvy required to turn science into real-world solutions. Such application of robust, proven technologies to find new solutions for new markets is creating a revolution across the world and is something at which Scotland excels.

Longer life expectancies in the developed world and a growing impetus to tackle threats to global health are driving a phenomenal acceleration in innovation and development among the life sciences community. It has been predicted that, within the year, biotechnology and healthcare products will account for 18% of GDP in the US.




This huge opportunity is already being seized by multinational companies such as 3Com ( http://www.3com.com/) and Cisco Systems ( http://www.cisco.com/), which provide communication solutions for telemedicine; Agilent ( http://www.agilent.com/), which develops LED tools for surgical visualization; IBM ( http://www.ibm.com/), which markets software tools for computational drug discovery; and GE Healthcare ( http://www.gehealthcare.com/), which provides next-generation cardiovascular imaging. Such organizations are leading the way by developing pioneering applications of new technologies for the healthcare and life sciences markets.

For Scotland's part, innovation in the fields of opto- and micro-electronics, engineering, and software is now being exploited by a commercially savvy new generation of convergence businesses driving products into these key global markets. Companies such as Biopta ( http://www.biopta.com/), Arrayjet ( http://www.arrayjet.co.uk/), Dimensional Imaging ( http://www.di3d.com/), and Touch Bionics ( http://www.touchbionics.com/) are all punching above their weight with a range of product solutions. Livingstone-based Craneware ( http://www.craneware.com/) is making a splash in the US market, selling financial management software solutions tailored to the specific needs of healthcare providers.




ITI Techmedia ( http://www.ititechmedia.com/) has also recently announced a new research and development program in the emerging area known as "theranostics." This exciting new field aims to combine diagnostic data with therapeutic solutions to customize treatments for individual patients. The program showcases the strength and depth of expertise found in Scotland's life sciences community, drawing on a multidisciplinary collaboration between Lab901 ( http://www.lab901.com/), Axis-Shield ( http://www.axis-shield.com/), and the Centre for Genomic Technology and Informatics at Edinburgh University ( http://www.gti.ed.ac.uk/).

Convergence companies, by the very nature of their business, are driven by collaboration and partnerships. Whether technical or commercial, the alliance of knowledge and expertise from different sectors and markets provides a compelling proposition.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here